[go: up one dir, main page]

NO20002960L - Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere - Google Patents

Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere

Info

Publication number
NO20002960L
NO20002960L NO20002960A NO20002960A NO20002960L NO 20002960 L NO20002960 L NO 20002960L NO 20002960 A NO20002960 A NO 20002960A NO 20002960 A NO20002960 A NO 20002960A NO 20002960 L NO20002960 L NO 20002960L
Authority
NO
Norway
Prior art keywords
men
urethral sphincter
bladder
dyssynergy
treatment
Prior art date
Application number
NO20002960A
Other languages
English (en)
Other versions
NO20002960D0 (no
Inventor
Risto Santti
Antti Talo
Tomi Streng
Kaija Halonen
Lauri Kangas
Risto Lammintausta
Original Assignee
Hormos Medical Oy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hormos Medical Oy Ltd filed Critical Hormos Medical Oy Ltd
Publication of NO20002960D0 publication Critical patent/NO20002960D0/no
Publication of NO20002960L publication Critical patent/NO20002960L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)

Abstract

Anvendelse av en aromataseinhibitor ved fremstilling av et farmasøytisk preparat for anvendelse ved behandling av i) detrusor uretral sfinkter-dyssynergi hos menn, hvori detrusor uretrale sfmkter-dyssynergien er uretral dysfunksjon som skyldes redusert forhold mellom androgen og østrogen i pasienten, eller ii) redusert forhold mellom androgen og østrogen hos menn. En fremgangsmåte for in v/vo-undersøkelse av påvirkningen av en bestemt tilstand på urinfunksjonen til mannlige individer ved anvendelse av en dyremodell av hanngnagere, hvori gnagerne er blitt utsatt for tilstanden, anestetisert, utstyrt med en trykktransduser forbundet med en inrusjonskanyle innsatt i blæren, en strømningsprobe innsatt i det distale urinrør og forbundet med et strømningsmeter, infusert med en løsning i blæren for å indusere vannlatning, og hvori blæretrykket og urinstrømmen registeres som en funksjon av tiden. Elektroder festes til muskler i den nedre urinkanal. Den elektriske aktivitet av musklene registreres samtidig med registreringen av blæretrykket og urinstrømmen.
NO20002960A 1997-12-12 2000-06-09 Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere NO20002960L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/989,447 US5972921A (en) 1997-12-12 1997-12-12 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
PCT/FI1998/000954 WO1999030708A2 (en) 1997-12-12 1998-12-09 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents

Publications (2)

Publication Number Publication Date
NO20002960D0 NO20002960D0 (no) 2000-06-09
NO20002960L true NO20002960L (no) 2000-08-14

Family

ID=25535123

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002960A NO20002960L (no) 1997-12-12 2000-06-09 Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere

Country Status (17)

Country Link
US (2) US5972921A (no)
EP (1) EP1043993B1 (no)
JP (1) JP2002508322A (no)
KR (1) KR20010032909A (no)
CN (1) CN1281361A (no)
AT (1) ATE235904T1 (no)
AU (1) AU743196B2 (no)
BR (1) BR9813534A (no)
CA (1) CA2312347A1 (no)
DE (1) DE69813025T2 (no)
EE (1) EE200000346A (no)
ES (1) ES2191358T3 (no)
HU (1) HUP0100762A3 (no)
NO (1) NO20002960L (no)
NZ (1) NZ504632A (no)
PL (1) PL341653A1 (no)
WO (1) WO1999030708A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
DE50016101D1 (de) * 1999-08-13 2011-06-09 Curadis Gmbh Substanzen und mittel zur positiven beeinflussung von kollagen
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
AR032316A1 (es) * 2000-04-12 2003-11-05 Novartis Ag Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
FI20010905A0 (fi) * 2001-05-02 2001-05-02 Vetcare Oy Uusi eläinlääke
US6607755B2 (en) * 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
US6931276B2 (en) * 2002-04-29 2005-08-16 Tomi Streng Method and device for use in micturition studies
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
AU2004266721A1 (en) * 2003-08-22 2005-03-03 University Of Virginia Patent Foundation Blockade of mTOR to prevent a hormonal adaptive response
KR101505884B1 (ko) * 2006-05-22 2015-03-25 호르모스 메디칼 리미티드 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
BR112014004879B1 (pt) * 2011-09-08 2020-01-28 Novartis Ag uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas, composição farmacêutica oral, e kit
CN102641502A (zh) * 2012-04-25 2012-08-22 中国农业大学 芳香酶抑制剂的新用途
US20170095520A1 (en) * 2014-03-21 2017-04-06 Dong Wha Pharm. Co., Ltd. A composition for preventing, treating, and improving of voiding dysfunction comprising extract of Piper longum L.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men

Also Published As

Publication number Publication date
CN1281361A (zh) 2001-01-24
ATE235904T1 (de) 2003-04-15
BR9813534A (pt) 2000-11-14
NO20002960D0 (no) 2000-06-09
WO1999030708A2 (en) 1999-06-24
CA2312347A1 (en) 1999-06-24
PL341653A1 (en) 2001-04-23
EE200000346A (et) 2001-10-15
KR20010032909A (ko) 2001-04-25
NZ504632A (en) 2001-10-26
EP1043993B1 (en) 2003-04-02
EP1043993A2 (en) 2000-10-18
AU743196B2 (en) 2002-01-24
JP2002508322A (ja) 2002-03-19
AU1489799A (en) 1999-07-05
HUP0100762A3 (en) 2002-12-28
DE69813025D1 (de) 2003-05-08
DE69813025T2 (de) 2004-01-15
HUP0100762A2 (hu) 2001-08-28
US6316431B1 (en) 2001-11-13
US5972921A (en) 1999-10-26
ES2191358T3 (es) 2003-09-01
WO1999030708A3 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
NO20002960L (no) Anvendelse av en aromataseinhibitor ved behandling av redusert androgen:østrogen-forhold og detrusor uretral sfinkter- dyssyneri hos menn, samt metode for undersøkelse av dyssynergi hos hanngnagere
Kamo et al. Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence
Hijaz et al. Animal models of female stress urinary incontinence
Farouk et al. Abnormal transient internal sphincter relaxation in idiopathic pruritus ani: physiological evidence from ambulatory monitoring
Patel et al. Pancreatic interstitial pH in human and feline chronic pancreatitis
Bradley Urinary bladder dysfunction in multiple sclerosis
EP1937143A2 (en) Techniques for evaluating urinary stress incontinence
Lee et al. Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats—effects of bladder outlet obstruction and intravesical PGE2
Eri et al. A prospective, placebo-controlled study of the antiandrogen Casodex as treatment for patients with benign prostatic hyperplasia
Shafik Straining urethral reflex: description of a reflex and its clinical significance: preliminary report
CN101485592B (zh) 电液化前列腺组织治疗探头
Nordling et al. Urethral electromyography using a new ring electrode
Petros et al. A mathematical model for micturition gives new insights into pressure measurement and function
Melman et al. Longitudinal studies of time‐dependent changes in both bladder and erectile function after streptozotocin‐induced diabetes in Fischer 344 male rats
Kirby et al. Non‐obstructive detrusor failure. A urodynamic, electromyographic, neurohistochemical and autonomic study
Reber et al. Feline model of chronic obstructive pancreatitis: effects of acute pancreatic duct decompression on blood flow and interstitial pH
Bradley et al. Combined electromyographic and gas urethral pressure profilometry
Kim et al. Diabetes slows the recovery from urinary incontinence due to simulated childbirth in female rats
Ito et al. Characterization of mouse neuro‐urological dynamics in a novel decerebrate arterially perfused mouse (DAPM) preparation
US20030204149A1 (en) Method and device for use in micturition studies
Shafik Study of the effect of external urethral sphincter contraction on the mechanical activity of the ureterovesical junction and urinary bladder: recognition of the sphinctero-ureterovesical reflex
Hasegawa et al. The effect of abdominal pressure on urinary flow rate
Bradley et al. Neuromuscular dysfunction of the lower urinary tract in patients with lesions of the cauda equina and conus medullaris
Hosokawa et al. Establishment of a new anal sphincter injury model in rats based on cardiotoxin
CN114557696A (zh) 一种泌尿外科用尿动力学测压管